"The initiative is a crucial step in establishing India as a leader in the clinical development of pharmaceutical agents," the Ministry of Health and Family Welfare said.
Under its Phase 1 clinical trials network, ICMR said it has formalized a Memorandum of Agreement (MoA) with multiple sponsors for four promising molecules.
As per the agreements, ICMR will carry out collaborative research on a small molecule for multiple myeloma (a blood cancer that affects plasma cells) with Bengaluru-based Aurigene Oncology.
The premier research body has partnered with Hyderabad-based Indian Immunologicals for the development of a Zika vaccine. It has coordinated with Bengaluru-based Mynvax Private for a trial of a vaccine against the seasonal flu virus.
ICMR also signed a pact with Navi Mumbai-based ImmunoACT to conduct a breakthrough study of CAR-T cell therapy for a new indication of chronic lymphocytic leukemia (a type of cancer of the blood and bone marrow). .
“The initiative positions India to emerge as a global leader in healthcare innovation. It is a key milestone in the quest for cutting-edge treatments that are affordable and accessible to all citizens,” said Union Minister for Health and Family Welfare J.P. Nadda.
“Establishing a phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to further expand this network, ensuring that India continues to lead the development of innovative and affordable healthcare solutions,” added Dr Rajiv Bahl, Secretary, Department of Health Research and Director General, ICMR.
The ICMR Network for Phase 1 Clinical Trials comprises four institutions strategically located in India, Mumbai; ACTREC, Navi Mumbai; SRM MCH and RC, Kattankulathur; and PGIMER, Chandigarh.
Under its Phase 1 clinical trials network, ICMR said it has formalized a Memorandum of Agreement (MoA) with multiple sponsors for four promising molecules.
As per the agreements, ICMR will carry out collaborative research on a small molecule for multiple myeloma (a blood cancer that affects plasma cells) with Bengaluru-based Aurigene Oncology.
The premier research body has partnered with Hyderabad-based Indian Immunologicals for the development of a Zika vaccine. It has coordinated with Bengaluru-based Mynvax Private for a trial of a vaccine against the seasonal flu virus.
ICMR also signed a pact with Navi Mumbai-based ImmunoACT to conduct a breakthrough study of CAR-T cell therapy for a new indication of chronic lymphocytic leukemia (a type of cancer of the blood and bone marrow). .
“The initiative positions India to emerge as a global leader in healthcare innovation. It is a key milestone in the quest for cutting-edge treatments that are affordable and accessible to all citizens,” said Union Minister for Health and Family Welfare J.P. Nadda.
“Establishing a phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to further expand this network, ensuring that India continues to lead the development of innovative and affordable healthcare solutions,” added Dr Rajiv Bahl, Secretary, Department of Health Research and Director General, ICMR.
The ICMR Network for Phase 1 Clinical Trials comprises four institutions strategically located in India, Mumbai; ACTREC, Navi Mumbai; SRM MCH and RC, Kattankulathur; and PGIMER, Chandigarh.
